(HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

Against all the odds, Roche's Genentech unit has won FDA approval for its clot-busting drug TNKase as a treatment for acute ischaemic stroke, after all but abandoning the project a couple of years ...

Genentech, the manufacturer of TNKase, says a new 25-mg vial configuration will be available in the coming months.